參考文獻 |
1. Perou, C. M.; Sørlie, T.; Eisen, M. B.; Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, ø.; Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A. -L.; Brown, P. O.; Botstein, D., Molecular portraits of human breast tumors. Nature 2000, 406, 747-752.
2. Sørlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Lønning, P. E.; Børresen-Dale, A. -L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001, 98, 10869-10874.
3. Bauer, K. R.; Brown, M.; Cress, R. D.; Parise, C. A.; Caggiano, V., Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007, 109, 1721-1728.
4. Tan, C.; Tasaka, H.; Yu, K. -P.; Murphy, M. L.; Karnofsky, D. A., Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 1967, 20, 333-353.
5. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F., Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 466-468.
6. Singal, P. K.; Iliskovic, N., Doxorubicin-induced cardiomyopathy. N. Engl. J. Med.1998, 339, 900-905.
7. De Beer, E. L.; Bottone, A. E.; Voest, E. E., Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur. J. Pharmacology 2001, 415, 1-11.
8. KB, W., Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003, 93, 105-115.
9. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D. D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, G.; Gabizon, A., Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals of oncology 2000, 11, 1029-1033.
10. Wall, M. E.; Wani, M. C., Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain memorial award lecture. Cancer research 1995, 55, 753-760.
11. McGuire, W. P.; Rowinsky, E. K.; Rosenshein, N. B.; Grumbine, F. C.; Ettinger, D. S.; Armstrong, D. K.; Donehower, R. C., Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 1989, 111, 273-279.
12. Wall, M. E.; Wani, M. C., Taxol; discovery to clinic. 1994, 6, 299-322.
13. Schiff, P. B.; Horwitz, S. B., Taxol stabilizes microtubules in mouse fibroblast cells. PNAS 1980, 77, 1561-1565.
14. Schiff, P. B.; Fant, J.; Horwitz, S. B., Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
15. Holton, R. A., Method for preparation of taxol using β-lactam. US 1992/5175315 A.
16. http://cisc.twbbs.org/
17. Kauffman, G. B., Michele Peyrone (1813-1883), Discoverer of cisplatin. Platinum Metals Rev. 2010, 54, 250-256.
18. Kauffman, G. B., Alfred Werner’s research on the platinum metals. Platinum Metals Rev. 1997, 41, 34-40.
19. Rosenberg, B.; Camp, L. V.; Krigas, T., Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205, 698-699.
20. Rosenberg, B., Platinum Coordination complexes in cancer chemotherapy. Naturwissenschaften 1973, 60, 399-406.
21. Chien, C. –T.; Yan, J. –Y.; Chiu, W. –C.; Wu, T. –H.; Liu, C. –Y.; Lin, S. –Y., Caged Pt nanoclusters exhibiting coorodibility to exert tumor-inside activation for anticancer chemotherapeutics. Adv. Mater. 2013, 25, 5067-5073.
22. Plooy, A. M.; Dijk, M., Lohman, P. H., Introduction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordinateon compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activety. Cancer research 1984, 44, 2043-2051.
23. Ha, H. -C.; Snyder, S. H., Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiology of disease 2000, 7, 225-239.
24. Farmer, H.; MoCabe, N.; Lord, C. J.; Tutt, A. N., J.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M. B.; Jackson, S. P.; Smith, G. C. M.; Ashworth, A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
25. O’ Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C., Iniparid plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364, 205-214.
26. O’ Shaughnessy, J.; Schwartzberg, L.; Danso, M. A.; Miller, K. D.; Rugo, H. S.; Neubauer, M.; Robert, N.; Hellerstedt, B.; Saleh, M.; Richards, P.; Specht, J. M.; Yardley, D. A.; Carlson, R. W.; Finn, R. S.; Charpentier, E.; Garcia-Ribas, I.; Winer, E. P., Phase Ⅲstudy of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2014, 32, 3840-3848.
27. Henson, D. E.; Hutter, R. V., P.; Myers, M. H., American joint committee on cancer 1988, 3, 145-150.
28. Sauzem, P. D.; Sant’Anna, G. S.; Machado, P.; Duarte, M. M.M.F.; Ferreira, J.; Mello, C. F.; Beck, P.; Bonacorso, H. G.; Zanatta, N.; Martins, M. A.P.; Rubin, M. A., Effect of 5-trifluoromethyl-4, 5-dihydro-1H-pyrazoles on chronic inflammatory pain model in rats. Eur. J. Pharmacol. 2009, 61, 91-100.
29. Padmaja, A.; Rajasekhar, C.; Muralikrishna, A.; Padmavathi, V., Synthesis and antioxidant activity of oxazolyl/thiazolylsulfonylmethyl pyrazoles and isoxazoles. Eur. J. Med. Chem. 2011, 46, 5034-5038.
30. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Terauchi, H.; Kawasaki, M.; Wachi, M.; Yamagishi, J. –I., Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl] pyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 4299-4303.
31. Shih, S. –R.; Chu, T. –Y.; Reddy, G. R.; Tseng, S. –N.; Chen, H. –L.; Tang, W. –F.; Wu, M. –S.; Yeh, J. –Y.; Chao, Y. –S.; Hsu, J. T.; Hsieh, H. –P.; Horng, J. –T., Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity. J. Biomed. Sci. 2010, 17, 1-9.
32. Koca, İ.; Özgür, A.; Coşkun, K. A.; Tutar, Y., Synthesis and anticancer activity of acyl thioureas bearing pyrazole moiety. Bioorg. Med. Chem. 2013, 21, 3859-3865.
33. Ngu, K.; Weinstein, D. S.; Liu, W.; Langevine, C.; Combs, D. W.; Zhuang, S.; Chen, X.; Madsen, C. S.; Harper, T. W.; Ahmad, S.; Robl, J. A., Pyrazole- based sulfonamide and sulfamides as potent inhibitors of mammalian 15-lipoxygenase. Bioorg. Med. Chem. 2011, 21, 4141-4145.
34. Barré, A; Ţînta̧s, M. –L.; Alix, F.; Gembus, V.; Papamicaël, C.; Levacher, V., Palladium-catalyzed carbonylation of (hetero)aryl, alkenyl and allyl halides by means of N-hydroxysuccinimidyl formate as CO surrogate. J. Org. Chem 2015, 80, 6537-6544. |